Paul Guichard, DO
Interventional Cardiology · Marietta, GANPI 1649269796
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $203,471 of the $260,408 with a category attached, or 78.1%. 36 manufacturers reported payments, led by United Therapeutics Corporation at 40.4% of the total. Among interventional cardiology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 637 payments — averaging $408.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$105K
- Actelion Pharmaceuticals US, Inc.$84K
- Bayer$31K
- Merck$30K
- Penumbra, Inc.$3K
- Inari Medical, Inc.$1K
- plus $6K from 30 others
Across 28 payments — averaging $4178.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Penumbra, Inc.$84K
- Actelion Pharmaceuticals US, Inc.$11K
- Actelion Pharmaceuticals, Ltd$11K
- Janssen Research & Development, LLC$7K
- Boston Scientific$2K
- EKOS Corporation$1K
What the payments were for
- Consulting fees$16,2806%
- Speaking & faculty fees$203,47178%
- Travel & lodging$19,9828%
- Food & beverage$20,6468%
- Education$290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 148 | $105,172 |
| Actelion Pharmaceuticals US, Inc. | 159 | $83,932 |
| Bayer | 46 | $31,214 |
| Merck | 49 | $30,010 |
| Penumbra, Inc. | 13 | $3,167 |
| Inari Medical, Inc. | 9 | $1,144 |
| Boston Scientific | 10 | $703 |
| Novartis | 41 | $690 |
| Pfizer | 28 | $500 |
| Edwards Lifesciences | 5 | $496 |
| Medtronic(2 entities) | 16 | $432 |
| Abiomed | 6 | $406 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $390 |
| Angiodynamics, Inc. | 4 | $376 |
| AstraZeneca | 15 | $301 |
| Novo Nordisk | 11 | $207 |
| W. L. Gore & Associates, Inc. | 7 | $150 |
| Boehringer Ingelheim | 7 | $122 |
| E.r. Squibb & Sons, L.L.C. | 8 | $122 |
| Shockwave Medical, Inc | 4 | $120 |
| Abbott | 2 | $115 |
| Amgen | 7 | $111 |
| Imperative Care, Inc | 3 | $95 |
| Johnson & Johnson | 9 | $73 |
| Sandoz | 2 | $59 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $39 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Scpharmaceuticals Inc. | 2 | $30 |
| Stryker | 1 | $29 |
| GSK | 1 | $27 |
| Lantheus Medical Imaging, Inc. | 1 | $27 |
| Impulse Dynamics (USA) Inc. | 1 | $26 |
| Cardiva Medical, Inc. | 1 | $23 |
| Philips North America LLC | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$71,689
- OPSUMIT$63,016
- TYVASO$41,069
- Adempas$30,321
- WINREVAIR$28,516
- ORENITRAM$23,227
- REMODULIN$16,524
- Indigo System$2,847
- FLOWTRIEVER CATHETER, S$715
- CT THROMBECTOMY SYSTEM KIT$715
- FlowTriever$343
- ClotTriever$343
- Impella$284
- GENERAL VASCULAR INTERVENTION$281
- AngioVac$234
- SYMPLICITY G3$163
- Penumbra System$161
How this compares
$260,408 in reported general payments places this provider in the 95th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 127 | $1,601,746 |
| AdempasRiociguat | 100 | $1,407,641 |
| UptraviSelexipag | 37 | $849,684 |
| Tyvaso DpiTreprostinil | 30 | $700,329 |
| EliquisApixaban | 492 | $591,049 |
| FarxigaDapagliflozin Propanediol | 115 | $111,776 |
| JardianceEmpagliflozin | 83 | $99,945 |
| XareltoRivaroxaban | 55 | $70,391 |
| EntrestoSacubitril/Valsartan | 54 | $60,394 |
| Ambrisentan | 21 | $47,655 |
| Repatha SureclickEvolocumab | 24 | $25,204 |
| Praluent PenAlirocumab | 25 | $16,604 |
| Sildenafil Citrate | 52 | $13,940 |
| BrilintaTicagrelor | 25 | $13,296 |
| Ranolazine ErRanolazine | 126 | $13,164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $83,932 | $2,451,430164 claims |
| BayerAdempas | $31,214 | $1,407,641100 claims |
| PfizerEliquis | $500 | $591,049492 claims |
| AstraZenecaFarxiga, Brilinta | $301 | $125,072140 claims |
| Boehringer IngelheimJardiance | $122 | $99,94583 claims |
| Johnson & JohnsonXarelto | $73 | $70,39155 claims |
| NovartisEntresto | $690 | $60,39454 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 218 interventional cardiology providers in Georgia.
Other interventional cardiology in Marietta
- Salvatore ManninoMarietta$275K
- Ahmed Al BadriMarietta$110K
- Arthur ReitmanMarietta$106K
- Amar PatelMarietta$73K
- Ateet PatelMarietta$24K
- William NicholsonAtlanta$1000K
- David KandzariAtlanta$982K
- Pradeep YadavAtlanta$656K
- Megan CoylewrightCalhoun$271K
- Adam GreenbaumAtlanta$238K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.